OWKIN Socrates

OWKIN Socrates is an AI-powered platform that aims to enhance drug discovery, clinical development, and collaborative medical research. According to the vendor, this platform is designed to cater to a wide range of businesses, including small to large pharmaceutical companies, biotech companies, academic research institutions, and healthcare organizations. It is utilized by various professionals and industries such as pharmaceutical and biotech researchers, data scientists, medical professionals, clinical researchers, biopharmaceutical companies, research institutions, healthcare providers, medical researchers, and data scientists.

Key Features

AI-powered drug discovery: According to the vendor, OWKIN Socrates utilizes cutting-edge machine learning and biology to advance drug discovery. It combines multimodal patient data and prior knowledge to identify novel drug targets and optimize drug positioning.

Optimizing clinical development: The vendor claims that OWKIN Socrates applies novel machine learning methodologies to optimize each phase of clinical development. It provides early estimates of efficacy, develops biomarker models, and uses data-driven covariate adjustment to increase statistical power and de-risk trial outcomes.

Collaborative medical research: According to the vendor, OWKIN Socrates facilitates secure and privacy-preserving collaborative research projects by connecting multiple partners. It supports federated learning and provides tools for consortium building and management.

Multimodal patient data analysis: The vendor states that OWKIN Socrates leverages multimodal patient data, including clinical data, histology, genomics, and other omics data. It combines data from multiple modalities to capture disease heterogeneity and the tumor microenvironment. The platform applies interpretable AI models to analyze patient data and identify biomarkers and subgroups.

External control arms for clinical trials: According to the vendor, OWKIN Socrates offers AI external control arms to provide early estimates of efficacy in single-arm phase I/II trials. It compares patient outcomes with predicted outcomes to improve efficacy analysis and de-risk early-stage trials.

AI & scientific expertise: The vendor highlights that OWKIN Socrates leverages OWKIN's AI expertise and strategic alliances with leading biopharmaceutical companies. It provides advanced analytics and insights in the healthcare industry, incorporating AI digital pathology diagnostics for accurate analysis and interpretation of pathology images.

Federated technologies: According to the vendor, OWKIN Socrates utilizes federated technologies to overcome data silos and increase the size and diversity of datasets. It enables secure collaboration of multiple organizations by allowing them to contribute and analyze their data without sharing it directly.

Regulatory: The vendor claims that OWKIN Socrates engages in continued conversations with regulators to ensure compliance with regulatory requirements in the healthcare industry. It is designed to facilitate regulatory compliance and provide transparency in data usage and analysis.

Inclusion criteria models: According to the vendor, OWKIN Socrates offers inclusion criteria models that help define subgroups of patients to improve clinical trial recruitment. These models utilize AI algorithms to identify specific patient populations based on drug mechanism of action and required biomarkers.

Covariate adjustment: The vendor states that OWKIN Socrates provides evidence-based covariate adjustment to improve the accuracy and reliability of clinical trial results. It identifies prognostic signals and leverages AI algorithms to adjust for covariates, enhancing the power and efficiency of randomized control arm clinical trials.